These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33387496)

  • 41. Case Series of 23 Patients Who Developed Fatal Radiation Pneumonitis After Stereotactic Body Radiotherapy for Lung Cancer.
    Onishi H; Marino K; Yamashita H; Terahara A; Onimaru R; Kokubo M; Shioyama Y; Kozuka T; Matsuo Y; Aruga T; Hiraoka M
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818801323. PubMed ID: 30286697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
    Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
    Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting?
    Drazer MW; Salama JK; Hahn OM; Weichselbaum RR; Chmura SJ
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):625-32. PubMed ID: 27078719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
    Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
    Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereotactic ablative radiotherapy for medically inoperable early stage lung cancer: early outcomes.
    Chan OS; Yeung RM; Hung AW; Lee MC; Chang AT; Chan CC; Lee AW
    Hong Kong Med J; 2012 Oct; 18(5):412-8. PubMed ID: 23018069
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunomodulatory effect of stereotactic ablative radiotherapy in lung cancer.
    Domagała-Kulawik J
    Pol Arch Intern Med; 2017 Apr; 127(4):233-234. PubMed ID: 28452968
    [No Abstract]   [Full Text] [Related]  

  • 47. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
    Iyengar P; Westover K; Timmerman RD
    Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stereotactic Body Radiotherapy - Current Indications.
    Burkoň P; Slavik M; Kazda T; Pospíšil P; Prochazka T; Vrzal M; Šlampa P
    Klin Onkol; 2019; 32(1):10-24. PubMed ID: 30894002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oligometastatic breast cancer.
    Kwapisz D
    Breast Cancer; 2019 Mar; 26(2):138-146. PubMed ID: 30324552
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Stereotactic ablative radiotherapy confirmed as a standard technique in NSCLC stage I].
    Hecht M; Fietkau R
    Strahlenther Onkol; 2019 Oct; 195(10):945-948. PubMed ID: 31410511
    [No Abstract]   [Full Text] [Related]  

  • 51. To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer.
    Shultz DB; Diehn M; Loo BW
    Semin Radiat Oncol; 2015 Apr; 25(2):78-86. PubMed ID: 25771411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CyberKnife Stereotactic Ablative Radiotherapy as an Option of Treatment for Patients With Prostate Cancer Having Oligometastatic Lymph Nodes: Single-Center Study Outcome Evaluation.
    Napieralska A; Miszczyk L; Stąpór-Fudzińska M
    Technol Cancer Res Treat; 2016 Oct; 15(5):661-73. PubMed ID: 26208835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereotactic ablative body radiotherapy (SABR): an alternative to surgery in stage I-II non-small-cell cancer of the lung?
    Mirimanoff RO
    Chin Clin Oncol; 2015 Dec; 4(4):42. PubMed ID: 26730754
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy.
    Milano MT; Katz AW; Schell MC; Philip A; Okunieff P
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1516-22. PubMed ID: 18495378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of stereotactic ablative radiotherapy in oncological and non-oncological clinical settings: highlights from the 7th Meeting of AIRO--Young Members Working Group (AIRO Giovani).
    Franco P; De Bari B; Ciammella P; Fiorentino A; Chiesa S; Amelio D; Pinzi V; Bonomo P; Vagge S; Fiore M; Comito T; Cecconi A; Mortellaro G; Bruni A; Trovò M; Filippi AR; Greto D; Alongi F;
    Tumori; 2014; 100(6):e214-9. PubMed ID: 25688503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible.
    Brunelli A
    J Thorac Cardiovasc Surg; 2018 Sep; 156(3):1247-1248. PubMed ID: 29754789
    [No Abstract]   [Full Text] [Related]  

  • 58. Stereotactic radiotherapy for pulmonary metastases.
    Chmura SJ; Salama JK; Weichselbaum RR
    Semin Thorac Cardiovasc Surg; 2013; 25(4):292-9. PubMed ID: 24673958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO).
    D'Angelillo RM; Francolini G; Ingrosso G; Ravo V; Triggiani L; Magli A; Mazzeo E; Arcangeli S; Alongi F; Jereczek-Fossa BA; Pergolizzi S; Pappagallo GL; Magrini SM
    Crit Rev Oncol Hematol; 2019 Jun; 138():24-28. PubMed ID: 31092381
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.